Company Encyclopedia
View More
name
Cathay Biotech
688065.SH
Cathay Biotech Inc., a bio-manufacturing technology company, researches, develops, produces, and sells bio-based materials in China and internationally. It offers biological long-chain diacids comprising sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine. The products are used in various applications, including textiles, pharmaceuticals, perfumes, automobiles, electronic appliances, consumer goods, and other industries. It provides its products under the TERRYL and ECOPENT brands.
1.968 T
688065.SHMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
B
Specialty ChemicalsIndustry
Industry Ranking4/153
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.10%C
    • Profit Margin18.08%A
    • Gross Margin43.09%B
  • Growth ScoreA
    • Revenue YoY18.96%B
    • Net Profit YoY49.43%B
    • Total Assets YoY27.91%A
    • Net Assets YoY41.55%A
  • Cash ScoreB
    • Cash Flow Margin553.09%C
    • OCF YoY18.96%B
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreA
    • Gearing Ratio9.50%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cathay Biotech: The net profit for the third quarter was 142 million yuan, a year-on-year increase of 45.30%

    Cathay Biotech announced that its revenue for the third quarter was 874 million yuan, a year-on-year increase of 13.43%; net profit was 142 million yuan, a year-on-year increase of 45.30%. Revenue for the first three quarters was 2.545 billion yuan, a year-on-year increase of 14.90%; net profit was 451 million yuan, a year-on-year increase of 30.56%

    Zhitong·
    SH
    688065
    +0.87%
    Zhitong·
    SH
    688065
    +0.87%

    Cathay Biotech: Accumulated over 10 million spent on share repurchase for incentives

    Shanghai Cathay Biotech Co., Ltd. announced the progress of its share repurchase. According to the plan approved by the board of directors, the repurchase amount is expected to be between 10 million and 20 million yuan, mainly for employee stock ownership plans or equity incentives. As of September 30, 2025, the company has repurchased 230,366 shares, accounting for 0.0319% of the total share capital, with a cumulative repurchase amount of 10,497,716.71 yuan, and the repurchase price ranged from 44.08 yuan to 53.40 yuan. The company will continue to promote the repurchase and disclose relevant information in a timely manner

    Zhitong·
    SH
    688065
    +0.87%
    Zhitong·
    SH
    688065
    +0.87%

    Cathay Biotech plans to launch an employee stock ownership plan in 2025

    Cathay Biotech announced the draft of its 2025 employee stock ownership plan, with participants including directors, senior management, and middle management, with an initial number of holders not exceeding 155. The plan will hold no more than 1.3 million shares, accounting for 0.18% of the company's total share capital. To attract and retain talent, 150,000 shares are reserved as a reserve quota, with a purchase price of 25.53 yuan/share

    Zhitong·
    SH
    688065
    +0.87%
    Zhitong·
    SH
    688065
    +0.87%

    Cathay Biotech authorizes its subsidiary for mutual guarantee, with a limit not exceeding 2 billion

    Shanghai Cathay Biotech Co., Ltd. announced that it has authorized its non-wholly-owned subsidiary to provide guarantees when applying for credit and during daily operations, with a limit not exceeding 2 billion yuan. Currently, the total amount of external guarantees provided by non-wholly-owned subsidiaries is 500 million yuan, all of which are inter-subsidiary guarantees, and there are no overdue or litigated guarantees. This authorization has been approved by the board of directors, the guarantee risk is controllable, and it does not harm the interests of the company and its shareholders

    Zhitong·
    SH
    688065
    +0.87%
    Zhitong·
    SH
    688065
    +0.87%

    Cathay Biotech: The annual production of 500,000 tons of bio-based hexanediamine and 900,000 tons of bio-based polyamide project has been postponed to December 31, 2027

    Cathay Biotech announced that the completion date for its 500,000 tons per year bio-based hexanediamine and 900,000 tons per year bio-based polyamide project will be postponed to December 31, 2027. The project, originally scheduled for completion on December 31, 2025, has been delayed due to the incomplete infrastructure of the industrial park. This adjustment complies with relevant laws and regulations and will not have a significant adverse impact on the company's normal operations

    Zhitong·
    SH
    688065
    +0.87%
    Zhitong·
    SH
    688065
    +0.87%